ArticleWorld journal of urology2026
Development and validation of a predictive model for calcium oxalate kidney stone recurrence integrating gut microbiome and clinical features.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo characterize the gut microbiome and clinical profiles of patients with recurrent calcium oxalate kidney stones, identify risk factors for recurrence, and develop an integrated predictive model.
methodsThe development and validation of the prediction model followed the reporting standards outlined in the TRIPOD checklist. In this prospective study, patients with a first calcium oxalate stone episode were enrolled and followed for two years. Gut microbiota were profiled using 16 S rDNA sequencing. Independent risk factors were identified by logistic regression, and a nomogram was constructed and validated with receiver operating characteristic curves, calibration plots, and decision curve analysis.
resultsAmong 268 patients, 75 (27.99%) developed recurrence. The recurrent group showed significantly lower gut microbial alpha diversity. LEfSe analysis revealed enrichment of Proteobacteria, Enterococcaceae, Limosilactobacillus, and Escherichia-Shigella, with reduced Firmicutes. Family history of stones (OR = 10.684), elevated serum creatinine (OR = 1.025), and increased Escherichia-Shigella relative abundance (OR = 1.063) were independent risk factors. The nomogram achieved an AUC of 0.978 in the training cohort and 0.943 in the validation cohort, with excellent calibration and net clinical benefit.
conclusionRecurrent calcium oxalate stone patients exhibit gut dysbiosis characterized by reduced diversity and Escherichia-Shigella enrichment. Family history, serum creatinine, and Escherichia-Shigella abundance independently predict recurrence. The nomogram integrating these factors provides a reliable tool for recurrence risk assessment.
Indexed as
Identifiers
42371145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.